The prevalence and severity of potential drug-drug interactions among adult polypharmacy patients at outpatient clinics in Jordan

被引:31
|
作者
Nusair, Mohammad B. [1 ]
Al-Azzam, Sayer, I [2 ]
Arabyat, Rasha M. [1 ]
Amawi, Haneen A. [1 ]
Alzoubi, Karem H. [2 ]
Rabah, Asma A. [1 ]
机构
[1] Yarmouk Univ, Fac Pharm, Irbid 21110, Jordan
[2] Jordan Univ Sci & Technol, Fac Pharm, Irbid 22110, Jordan
关键词
Polypharmacy; Drug-drug interactions; Lexicomp (R); Medication management; INTERACTION SOFTWARE; ELDERLY-PEOPLE; CARE; PRESCRIPTIONS;
D O I
10.1016/j.jsps.2019.11.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To assess the prevalence of potential drug-drug interactions (pDDIs) among polypharmacy patients in Jordan using Lexicomp (R). Additionally, this study aims to categorize and rate the identified pDDIs according to interaction risk, severity, and reliability. Methods: A descriptive cross-sectional study was conducted at six different hospitals representing different public health sectors in Jordan (ministry of health, royal medical services, and university-affiliated hospitals). Polypharmacy patients from outpatient clinics (e.g., cardiology,& and internal medicine) were identified, recruited, and interviewed by clinical pharmacists. pDDIs were assessed using the Lexicomp (R) mobile application and classified according to interaction risk rating, severity, and reliability rating. Furthermore, the prevalence of pDDIs across chronic medical conditions was assessed. P-value <0.05 was considered as significant. Results: A total of 801 patients with polypharmacy were identified. The average number of drugs per patient was 6.6 +/- 1.96, with an average of 4.2 +/- 3.0 pDDIs per patient. Potential drug-drug interactions were detected in 769 patients (96%), with a total of 3359 interactions. Blood pressure lowering agents were involved in 39.9% of the pDDIs. Cardiovascular system drugs contributed to the largest share of pDDIs (46.6%). While diuretics had the major share of interactions among cardiovascular system drugs (16.2%), drugs used in diabetes had the highest share across all groups (17.1%). The majority of pDDIs were of "C" risk rating with a moderate interaction severity, whilst 1.6% of pDDIs could have been avoided in the first place as the concurrent administration of these agents is contraindicated (i.e., risk rating X). Patients with cardiovascular diseases, diabetes, chronic obstructive pulmonary disease, gout, and chronic kidney disease were associated with the highest number of potential drug-drug interactions. Conclusion: Our study showed that 96% of polypharmacy patients at outpatient clinics have at least one pDDI. Almost half of the detected interactions involved cardiovascular medications. The majority of these pDDIs had moderate severity, with no more than 10% of the interactions requiring therapy modification. (C) 2019 The Author(s). Published by Elsevier B.V. on behalf of King Saud University.
引用
收藏
页码:155 / 160
页数:6
相关论文
共 50 条
  • [1] Prevalence and Severity of Potential Drug-Drug Interactions in Patients with Multiple Sclerosis with and without Polypharmacy
    Bachmann, Paula
    Frahm, Niklas
    Debus, Jane Louisa
    Mashhadiakbar, Pegah
    Langhorst, Silvan Elias
    Streckenbach, Barbara
    Baldt, Julia
    Heidler, Felicita
    Hecker, Michael
    Zettl, Uwe Klaus
    PHARMACEUTICS, 2022, 14 (03)
  • [2] Prevalence of polypharmacy and risk of potential drug-drug interactions among hospitalized patients with emphasis on the pharmacokinetics
    Georgiev, Kaloyan D.
    Hvarchanova, Nadezhda
    Stoychev, Elitsa
    Kanazirev, Branimir
    SCIENCE PROGRESS, 2022, 105 (01)
  • [3] The Prevalence of Polypharmacy and Potential Drug-Drug Interactions among Iranian Cancer Patients: Which Patients were at Risk?
    Bazrafshani, Maliheh Sadat
    Pardakhty, Abbas
    Khandani, Behjat Kalantari
    Nasiri, Naser
    Moghaderi, Masoud
    Bazrafshani, Azam
    Mehmandoost, Soheil
    Beigzadeh, Amin
    Sharifi, Hamid
    CANCER INVESTIGATION, 2022, 40 (05) : 457 - 472
  • [4] Polypharmacy in hematology and oncology patients and the resulting prevalence of potential drug-drug interactions (DDI)
    Metzke, B.
    Fink, G.
    Hieke, S.
    Jung, M.
    Hug, M. J.
    Engelhardt, M.
    ONKOLOGIE, 2012, 35 : 76 - 76
  • [5] Polypharmacy and drug-drug interactions among patients with ulcerative colitis
    Esteban, Figueroa
    Overby, M.
    Brian, Behm
    Takahiro, Nakamura
    Brian, Wentworth
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S25 - S26
  • [6] Polypharmacy and potential drug-drug interactions in emergency department patients in the Caribbean
    Dookeeram, Darren
    Bidaisee, Satesh
    Paul, Joanne F.
    Nunes, Paula
    Robertson, Paula
    Maharaj, Vidya Ramcharitar
    Sammy, Ian
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2017, 39 (05) : 1119 - 1127
  • [7] Potential drug-drug interactions in the outpatient setting
    Lafata, JE
    Schultz, L
    Simpkins, J
    Chan, KA
    Horn, JR
    Kaatz, S
    Long, C
    Platt, R
    Raebel, MA
    Smith, DH
    Xi, HG
    Yood, MU
    MEDICAL CARE, 2006, 44 (06) : 534 - 541
  • [8] Polypharmacy and the occurrence of potential drug-drug interactions among geriatric patients at the outpatient pharmacy department of a regional hospital in Durban, South Africa
    Bojuwoye, Adetola Olaniyi
    Suleman, Fatima
    Perumal-Pillay, Velisha Ann
    JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE, 2022, 15 (01)
  • [9] Prevalence and clinical significance of potential drug-drug interactions among lung transplant patients
    Zhang, Jiali
    Ma, Danyi
    Chen, Meng
    Hu, Yanting
    Chen, Xveying
    Chen, Jingyu
    Huang, Man
    Dai, Haibin
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [10] Prevalence and significance of potential drug-drug interactions among cancer patients receiving chemotherapy
    Ismail, Mohammad
    Khan, Sehrash
    Khan, Fahadullah
    Noor, Sidra
    Sajid, Hira
    Yar, Shazia
    Rasheed, Irum
    BMC CANCER, 2020, 20 (01)